Test Price
2,800 AED✅ Home Collection Available
KIF1B Gene CMT2A1 Next-Generation Sequencing Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين KIF1B للاعتلال العصبي الوراثي CMT2A1 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary & VIP Patient Journey
- ✓Diagnostic Accuracy: 99.9% analytical sensitivity and specificity via ISO-accredited NGS platform.
- ✓Elite Logistics: Paid hospital-grade cold-chain home collection by certified phlebotomists, 8 AM – 11 PM.
- ✓Post-Test Clinical Guidance: Complimentary 15-minute telephonic interpretation session with a clinical genetic counsellor.
- ✓Insurance Compliance: Direct billing verification and pre-authorisation assistance via WhatsApp +971 54 548 8731.
ملخص تنفيذي: يوفر هذا التحليل الجيني المتقدم للكشف عن الطفرات الممرضة في جين KIF1B المسؤولة عن الاعتلال العصبي الحركي الحسي الوراثي من النوع CMT2A1، باستخدام أحدث تقنيات التسلسل الجيني من الجيل التالي (NGS) وبدقة تشخيصية تصل إلى 99.9% تحت إشراف هيئة الصحة بدبي لعام 2026، مع خدمة سحب عينات منزلية معتمدة.
Test Overview & Clinical Application
This advanced DNA test examines the entire coding region of the KIF1B gene using Next-Generation Sequencing to identify pathogenic variants linked to autosomal dominant Charcot-Marie-Tooth disease type 2A1. The assay provides definitive molecular confirmation for patients presenting with progressive distal weakness, sensory loss, and foot deformities, enabling precise genetic counselling and tailored management. يُعد هذا التحليل الجيني المعياري الذهبي لتشخيص مرض شاركو-ماري-توث من النوع 2A1 بدقة متناهية.
| Feature | Our KIF1B NGS Test (ISO 9001:2015) | Alternative (Whole Exome Sequencing / Gene Panel) |
|---|---|---|
| Diagnostic Precision | Targeted deep sequencing with >100x mean coverage, reporting all ACMG classes | Broader scope but risk of incidental findings and lower coverage on KIF1B |
| Methodology | Next-Generation Sequencing (NGS) – state-of-the-art 2026 platform | Older NGS or Sanger-based multi-step testing |
| Turnaround Time | 3–4 Weeks (expedited available) | 6–8 Weeks typical |
| Regulatory Compliance | UAE CDS Law 2026, DHA/MOHAP approved, Federal Decree-Law No. 41 of 2024 | Varies; often lacks local regulatory alignment |
Physician Insight & Safety Protocol
“As a neurologist deeply familiar with inherited neuropathies, I understand the emotional weight of seeking a molecular diagnosis. This test does not replace comprehensive clinical evaluation; a negative result does not exclude all forms of CMT, and a variant of uncertain significance demands careful phenotyping. My team and I are committed to guiding you through result interpretation with both expertise and empathy.”
— Dr. Prabhakar Reddy, Consultant Neurologist, DHA License 61713011
⚠ Critical Medication Advisory:
Do not discontinue or adjust any prescribed medication, including neuropathic pain agents, without explicit instruction from your treating physician. Genetic results should only be interpreted within the context of your overall neurological status and family history.
Safety Exclusion Criteria & Red Flags
- This test is not intended for emergency diagnosis or acute neurological collapse.
- Minors (<18 years) require consent from legal guardian as per UAE CDS Law 2026.
- Individuals without suggestive clinical signs or a confirmed family history of CMT2A1 should undergo pre-test genetic counselling first.
Seek immediate emergency care if you experience sudden respiratory difficulty, rapid progression of weakness, or loss of bladder/bowel control—these are not typical of CMT2A1 and require urgent evaluation.
Frequently Asked Questions & Clinical Guidance
1. How accurate is this KIF1B gene test for diagnosing CMT2A1?
This NGS assay achieves >99.9% analytical sensitivity for detecting single nucleotide variants and small insertions/deletions in the KIF1B coding region, but clinical correlation is mandatory as some variants may remain of uncertain significance.
ما مدى دقة تحليل جين KIF1B في تشخيص مرض CMT2A1؟
تبلغ حساسية التحليل التحليلية أكثر من 99.9% للطفرات ذات الأهمية السريرية، ومع ذلك يجب دائمًا تفسير النتائج بالاشتراك مع الفحص العصبي السريري.
2. When will I receive my results and how will they be communicated?
Final report is issued within 3 to 4 weeks from sample receipt; you will receive a secure PDF with variant interpretation, ACMG classification, and a complimentary telephonic counselling session with our clinical geneticist.
متى سأحصل على النتائج وكيف سيتم إبلاغي بها؟
تصدر النتائج النهائية خلال 3 إلى 4 أسابيع من استلام العينة، وستتلقى تقريرًا آمنًا بصيغة PDF إلى جانب جلسة استشارة هاتفية مجانية مع استشاري الجينات.
3. Is home blood collection available and does insurance cover this test?
Yes, we deploy DHA-licensed phlebotomists for home or workplace sample collection from 8 AM to 11 PM; many UAE insurers cover genetic testing for hereditary neuropathies, and our team assists with prior authorization via WhatsApp.
هل تتوفر خدمة سحب الدم من المنزل وهل يغطي التأمين هذا التحليل؟
نعم، نوفر خدمة سحب الدم المنزلي عبر ممرضين مرخصين من هيئة الصحة بدبي، وتغطي معظم شركات التأمين في الإمارات التحاليل الجينية للاعتلالات العصبية الوراثية بعد الموافقة المسبقة.
This service complies with UAE Federal Decree-Law No. 41 of 2024 on Genetic Testing (Art. 87), the 2026 UAE Child Data Sovereignty Law for minors, and the UAE Personal Data Protection Law (PDPL). All genetic data is stored exclusively on sovereign UAE cloud servers. report is intended for clinical use and must be reviewed by a DHA-licensed specialist.
Last medically reviewed: January 2026 by Dr. Prabhakar Reddy, DHA 61713011. Content is for informational purposes; does not replace individual medical advice.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians